Predictions
Biora Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.09
02.03.24
02.03.24
€1.00
02.03.25
02.03.25
-0.92%
16.03.24
16.03.24
Cardiff Oncology Inc.
Start price
Target price
Perf. (%)
€2.54
02.03.24
02.03.24
€4.00
02.03.25
02.03.25
82.48%
16.03.24
16.03.24
Adicet Bio Inc.
Start price
Target price
Perf. (%)
€2.23
02.03.24
02.03.24
€22.00
02.03.25
02.03.25
-19.90%
16.03.24
16.03.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
EBIT growth > 30% per year expected
Park Hotels & Resorts Inc
Start price
Target price
Perf. (%)
€15.80
01.03.24
01.03.24
€19.42
01.03.25
01.03.25
-12.10%
09:31
09:31
Minim Inc.
Start price
Target price
Perf. (%)
€7.15
01.03.24
01.03.24
-
01.03.25
01.03.25
-35.38%
01.03.24
01.03.24
Probably not worthwhile Investment
Microbot Medical Inc
Start price
Target price
Perf. (%)
€1.23
29.02.24
29.02.24
€3.69
28.02.25
28.02.25
-33.70%
04.10.24
04.10.24
Everspin Technologies Inc
Start price
Target price
Perf. (%)
€7.70
29.02.24
29.02.24
€11.07
28.02.25
28.02.25
-31.82%
04.10.24
04.10.24
HelloFresh SE
Start price
Target price
Perf. (%)
€13.19
29.02.24
29.02.24
€14.00
28.02.25
28.02.25
-42.68%
16.03.24
16.03.24
Could be worthwhile Investment >10% per year
Revenue growth >5% per year expected
EBIT growth >5% per year expected
Fair valuation
Protagonist Therapeutics Inc
Start price
Target price
Perf. (%)
€21.80
28.02.24
28.02.24
€34.13
28.02.25
28.02.25
-
24.02.22
24.02.22
Protagonist Therapeutics Inc
Start price
Target price
Perf. (%)
€21.80
28.02.24
28.02.24
€35.09
28.02.25
28.02.25
-
24.02.22
24.02.22
Alterity Therapeutics Ltd. ADR
Start price
Target price
Perf. (%)
€1.29
28.02.24
28.02.24
€1.00
28.02.25
28.02.25
0.00%
02.03.24
02.03.24
Biora Therapeutics Inc.
Start price
Target price
Perf. (%)
€1.43
28.02.24
28.02.24
€0.000
28.02.25
28.02.25
-23.78%
02.03.24
02.03.24
Adicet Bio Inc.
Start price
Target price
Perf. (%)
€2.18
28.02.24
28.02.24
€22.00
28.02.25
28.02.25
2.29%
02.03.24
02.03.24
Could be very worthwhile Investment >20% year
Revenue growth > 30% per year expected
Rising EBIT margin expected
EBIT growth > 30% per year expected